Formulation Design and In-vitro Characterization of Docetaxel Cubosomes for Gastric Cancer therapy

Cubosomes are altered cubic phase systems, which are emerging as promising drug delivery system for the delivery of both hydrophilic and lipophilic drugs. Docetaxel is an antineoplastic agent that has a unique mechanism of action as an inhibitor of cellular mitosis and that currently plays a central role in the therapy of many solid tumors including breast and lung cancer. Docetaxel in the form of cubosomes. The main aim of present research was to encapsulate, Docetaxel in cubosomes for sustained drug release. Docetaxel loaded cubosomes were prepared by Bottom-Up Method technique using Glyceryl Mono Oleate and pluronic F-127 and Pluronic F68 in different ratios. The prepared formulations were subjected to evaluation studies for excipient compatibility, particle size, drug content, entrapment efficiency and In vitro drug release. The maximum entrapment efficiency was found as 90.15% with, and In vitro drug release as 99.37%. Stability studies were also conducted for the formulations as per protocol mentioned in ICH guidelines. These results suggest that the cubosomal formulation F4 is suitable for the delivery of Docetaxel.